Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | PGK1 | P00558 | 11/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765894 | 0.88 | CSNK1A1 (0.50) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4768640 | 0.86 | POLB (0.49) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4770518 | 0.85 | CSNK1A1 (0.47) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4768126 | 0.84 | CNR1 (0.46) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4773544 | 0.82 | CSNK1A1 (0.55) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL27502303 | 0.82 | CSNK1A1 (0.51) | CSNK1A1CLK4PIN1ALDH1A1LMNA | |
| SCHEMBL4772159 | 0.82 | CSNK1A1 (0.47) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4763576 | 0.82 | CSNK1A1 (0.44) | CSNK1A1CLK4PGK1LRRK2PIN1 | |
| SCHEMBL4765379 | 0.82 | CSNK1A1 (0.44) | CSNK1A1CLK4PIN1L3MBTL1ALDH1A1 | |
| SCHEMBL4579364 | 0.82 | SMN1; SMN2 (0.45) | CSNK1A1CLK4PIN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | CSNK1A1 702/4885CLK4 3635/4885PGK1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.